GLP-1 receptor agonists such as semaglutide and tirzepatide are FDA-regulated for chronic weight management in adults with a BMI of 30 or higher, or 27 with a weight-related condition. Las Vegas runs around the clock, and dealers, servers, performers and resort staff working overnight and rotating shifts rarely fit a daytime clinic into their week - even as the job keeps appearance and stamina front of mind. Telehealth works on their clock: a licensed Nevada physician reviews your online assessment under Nevada Revised Statutes §629.515, and compounded medication from an FDA-registered 503B pharmacy ships to your Las Vegas address. Monthly cost runs $199–$379 versus about $1,247 for brand-name Ozempic or Wegovy. Medical Director: Dr. Steven Nguyen, MD, Board-Certified Internal Medicine. Serving Las Vegas ZIP codes: 89101, 89102, 89104, 89109, 89119.
Local clinics serving Las Vegas: Genesis Lifestyle Medicine, Premier Physicians Weight Loss & Wellness and LightFit. Many patients compare these in-person options against licensed GLP-1 telehealth — prescribed online, shipped to the door.
Tirzepatide seen from Las Vegas, without the jargon. In head-to-head comparisons, tirzepatide has posted some of the highest average weight-loss numbers ever measured for a non-surgical treatment.
Pregnancy and breastfeeding are among the situations where these treatments are not indicated. The goal of the evaluation is not to screen for the sake of screening, but to make sure the expected benefit outweighs the risks.
Local landmark: Genesis Lifestyle Medicine (7455 W Washington Ave # 140), rated 4.9/5 across 434 reviews. Typical dosing: 2.5 - 5 - 7.5 - 10 - 12.5 - 15 mg/week, stepped up by tolerance and goal. The area's median income (~$66,356) weighs on the brand-vs-compounded trade-off in Las Vegas. Around Las Vegas in Clark County, 3 weight-management practice(s) are listed locally.
Yes: both are tirzepatide. Mounjaro is dosed/labeled for type 2 diabetes, Zepbound for weight management.
Often a BMI of 30 or higher, or 27 or higher with a weight-related comorbidity, but only the medical evaluation decides.
In the SURMOUNT head-to-head trials, tirzepatide produced greater average weight loss, likely thanks to its dual GIP + GLP-1 action. Response is individual and should be assessed by a physician.
Medical Director: Dr. Steven Nguyen, MD, Board-Certified Internal Medicine. Licensed in Nevada. All prescriptions issued under Nevada Revised Statutes §629.515 and supervised by Nevada State Board of Medical Examiners.